Citi raised the firm’s price target on Establishment Labs (ESTA) to $47 from $38 and keeps a Neutral rating on the shares. The firm adjusted targets in medical technology as part of a Q2 earnings preview.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs Holdings: Strong Buy Rating Driven by Motiva Implants’ Growing Demand and Innovation
- Strong Buy Recommendation for Establishment Labs Holdings Driven by US Launch Momentum and Promising Pipeline
- Promising Outlook for Establishment Labs: Buy Rating Affirmed Amid Strong Market Potential and Financial Guidance
- Establishment Labs Holdings: Strong Growth Potential and Strategic Initiatives Drive Buy Rating
- Establishment Labs Launches Motiva Implants in U.S.